Skip to main content

Table 4 Complications after CRS and HIPEC

From: Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study

 

Experimental group N = 8

Control group N = 88

Cardiovascular

1 (12.5%)

20 (18.1%)

Pulmonary

2 (25%)

12 (10.9%)

Gastrointestinal

3 (37.5%)

31 (28.2%)

Sepsis/SIRS

2 (25%)

9 (8.1%)

Mental

1 (12.5%)

12 (10.9%)

Wound

2 (25%)

7 (6.4%)

Anastomotic leakage

0 (0%)

8 (7.2%)

Neurological

1 (12.5%)

2 (1.8%)

Nephrological

0 (0%)

19 (17.3%)

  1. CRS cytoreductive surgery, HPEC hyperthermic intraperitoneal chemotherapy